source
- Altimmune rises as GLP-1/glucagon drug curbs heavy drinking in mid-stage studyPemvidutide showed a “highly statistically significant” treatment effect in patients with alcohol use disorder. Altimmune is going up against Eli Lilly and newcomer Baseline Therapeutics, among oth…
- Apnimed eyes up to $160M IPO to prep for sleep apnea drug launchIf the offering closes, Apnimed will join the 2026 IPO class that has already far surpassed last year’s total.